Prestige Consumer Healthcare (PBH) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 513.2% versus a loss of 23.2%. Over five years, SLS leads with a +27.5% price change compared with -17.4% for PBH. SELLAS Life Sciences Group is the larger company by market cap ($2.35 billion vs $2.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBH | SLS |
|---|---|---|
| Share price | $48.23 | $11.65 |
| Market cap | $2.28B | $2.35B |
| 1-day change | +0.75% | +3.46% |
| YTD return | -21.82% | +209.02% |
| 1-year return | -23.19% | +513.16% |
| 5-year return | -17.44% | +27.52% |
| P/E ratio (TTM) | 13.51 | — |
| Forward P/E | 9.49 | — |
| EPS (TTM) | $3.57 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.09B | — |
| Revenue growth (YoY) | -4.31% | — |
| Net income (latest FY) | $190.30M | $-26.86M |
| Gross margin | 54.71% | — |
| Operating margin | 28.42% | — |
| Net margin | 17.48% | — |
| 52-week high | $71.07 | $15.88 |
| 52-week low | $42.62 | $1.39 |
| Distance from 52-week high | -32.14% | -26.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +40.58% | +178.97% |
| Average volume | 547.31K | 6.52M |
| Shares outstanding | 47.37M | 201.95M |
| Employees | 890 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed PBH by 536.3 percentage points over the past year.
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
PBH vs SLS FAQ
Which is bigger, Prestige Consumer Healthcare or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.35B compared with $2.28B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, PBH or SLS?
SLS returned +513.16% over the past 12 months, compared with -23.19% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Prestige Consumer Healthcare and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.